<DOC>
	<DOCNO>NCT00663455</DOCNO>
	<brief_summary>The purpose study determine safe reduction cyclosporine A pediatric adolescent patient stable renal graft function , reduce sign calcineurin-inhibitor toxicity .</brief_summary>
	<brief_title>Randomized Study Reduce Calcineurininhibitor Toxicity Pediatric Adolescent Kidney Transplant Recipients</brief_title>
	<detailed_description>Chronic transplant nephropathy one major cause graft loss renal transplantation . Toxicity calcineurin-inhibitors suspect one cause loss graft function . Therefore reduction cyclosporine A dosing result longer graft survival well graft function patient renal-transplantation . However , reduction immunosuppression result acute rejection episode , although less likely patient stable graft function 12 month longer successful renal transplantation . Therefore aim randomize , control study pediatric adolescent renal transplant recipient , compare impact reduce cyclosporine A-dosing standard CSA-dosing renal graft function . Therapy monitoring group perform obtain CSA blood level two hour intake , provide individual insight pharmacokinetics comparison conventional trough level ( C0 ) -measurements . Secondary objective evaluate 1. evaluation health-related Quality life psychosocial burden two treatment arm . 2. measurement NFAT-regulated gene expression ( nuclear factor activate t-cells ) intracellular cytokine [ Interleukin-2 , TNF-alpha , Interferon-gamma GMCSF ) quantitative PCR measurement CSA activity . 3 . To obtain new insight screen metabolite conjunct clinic feature nephrotoxicity graft rejection metabolomic screen target analysis ( trimethylamine-N-oxide , neopterin kynurenine/tryptophan ratio ) perform .</detailed_description>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>age inclusion 316 year male female patient recipient first second renal transplant graft age &gt; 24 month last acute rejection episode &gt; 6 month ago Immune suppression comedication Mycophenolatmofetil ( MMF ) dose range 1200 +/ 200 mg/m² BSA/d within least 6 month minimal MPAAUC ≥ 45 mg x h/l . If MPAAUC &lt; 45 mg x h/l adjustment dosage rescreening ≥ 4 week possible . Application CSA stable dosing within last 3 month study inclusion CSAC2level &gt; 500 ng/ml . If CSAC2level &lt; 500 ng/ml adjustment dosage rescreening ≥ 4 week possible . steroidfree immunosuppression least 6 month enrollment biopsy renal graft without sign acute rejection ( def . accord BANFF classification ) , within 3 month enrollment write informed consent parents/legal guardian , applicable , patient 's consent glomerular filtration rate &lt; 40 ml/min/1.73 m2 BSA ( acc . Schwartz ' formula ) time enrollment &gt; 2 episode acute graft rejection within 12 month prior enrollment condition steroidresistant graft rejection actual participation another clinical trial Recurrence primary renal disease graft proven infection EBV and/ CMV antiviral therapy within 3 month prior enrollment proven infection polyoma virus within 3 month prior enrolment pregnant nursing woman hemoglobin &lt; 8 g/dl screen visit nontreated arterial hypertension uncontrolled infectious disease history malignancy organ system , treat nontreated</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>kidney transplant recipient</keyword>
	<keyword>child adolescent kidney transplant</keyword>
</DOC>